Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
Babar Bashir, Douglas F Stickle, Inna Chervoneva, Walter K Kraft, Babar Bashir, Douglas F Stickle, Inna Chervoneva, Walter K Kraft
Abstract
Apixaban is metabolized by cytochrome P450 (CYP) 3A4 in the liver and intestine, undergoes direct intestinal excretion, and is a substrate to permeability glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. We examined the drug interactions between cyclosporine and tacrolimus (combined inhibitors of CYP3A4, P-gp, and BCRP) with apixaban in 12 healthy adult male volunteers. Apixaban 10 mg was administered orally alone, in combination with 100 mg cyclosporine or 5 mg tacrolimus. Co-administration with cyclosporine resulted in increase in apixaban maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC(0-tlast) ) with associated geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of 143% (112, 183) and 120% (97, 148), respectively. Co-administration with tacrolimus resulted in reduction in apixaban Cmax and AUC(0-tlast) with associated GMRs (90% CI) of 87% (69, 112) and 78% (63, 97), respectively. The observed changes in apixaban exposure margins with cyclosporine or tacrolimus are within the range of the historical clinical development program, therefore, apixaban dose adjustments are not warranted.
© 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Figures
References
- Starzl, T.E. et al The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg. Gynecol. Obstet. 1, 17–26 (1980).
- Scalea, J.R. , Levi, S.T. , Ally, W. & Brayman, K.L. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Exp. Rev. Clin. Immunol. 3, 333–342 (2016).
- Zanazzi, M. et al Venous thromboembolism in renal transplant recipients: High rate of recurrence. Transpl. Proc.. 6, 2493–2494.
- Allen, R.D. , Michie, C.A. , Murie, J.A. & Morris, P.J. Deep venous thrombosis after renal transplantation. Surg. Gynecol. Obstet. 2, 137–142 (1987).
- Arnadottir, M. et al Thromboembolic complications after renal transplantation: a retrospective analysis. World J. Surg. 6, 757–761 (1983).
- Poli, D. et al Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. J. Thromb. Haemost. 5, 988–992 (2006).
- Poli, D. et al High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation 6, 789–793 (2005).
- Yip, J. et al Deep vein thrombosis and pulmonary embolism in liver transplant patients: risks and prevention. Transplant. Direct. 4, e68 (2016).
- Alexander, B.R. et al Chemoprophylaxis use and risk of venous thromboembolism and death in adult patients following orthotopic liver transplantation. J. Pharm. Pract. 3, 218–223 (2016).
- Alvarez Alvarez, R.J. et al Venous thromboembolism in heart transplant patients: incidence, clinical characteristics and risk factors. J. Heart Lung Transplant.. 4, S135–S136 (2015).
- Aboagye, J.K. et al Venous thromboembolism in patients hospitalized for lung transplantation. Ann. Thorac. Surg.. 4, 1071–1076 (2018).
- Lentine, K.L. et al Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin. J. Am. Soc. Nephrol. 2, 288–296 (2006).
- Orrego, C.M. et al Atrial arrhythmias after lung transplant: underlying mechanisms, risk factors, and prognosis. J. Heart Lung Transplant.. 7, 734–740 (2014).
- Hamon, D. , Taleski, J. , Vaseghi, M. , Shivkumar, K. & Boyle, N.G. Arrhythmias in the heart transplant patient. Arrhythm. Electrophysiol. Rev. 3, 149–155 (2014).
- Wong, P.C. et al Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 5, 820–829 (2008).
- Barnes, G.D. , Lucas, E. , Alexander, G.C. & Goldberger, Z.D . National trends in ambulatory oral anticoagulant use. Am. J. Med.. 12, 1300–1305 (2015).
- Wang, L. et al In vitro assessment of metabolic drug‐drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab. Dispos. 3, 448–458 (2010).
- Apixaban (ELIQUIS®) tablets for oral use. U.S. Full prescribing information. (Bristol‐Myers Squibb Company, Princeton, NJ, and Pfizer Inc. New York, NY (2016) August 10, 2016.
- Zhang, D. et al Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab. Dispos. 4, 827–835 (2013).
- Frost, C.E. et al Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 5, 838–846 (2015).
- Cyclosporine (NEORAL®) soft gelatin capsules for oral use: U.S. Full prescribing information. (Novartis Pharmaceuticals Corporation, East Hanover, NJ. 2015).
- Tacrolimus (PROGRAF®) capsules for oral use: U.S. full prescribing information. (Astellas Pharma US, Inc. Northbrook, IL. 2015); August 20, 2016.
- Barbarino, J.M. , Staatz, C.E. , Venkataramanan, R. , Klein, T.E. & Altman, R.B. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet. Genomics 10, 563–585 (2013).
- The International Transporter Consortium, et al. Membrane transporters in drug development. Nat. Rev. Drug Discovery 3, 215–236 (2010).
- Amundsen, R. , Åsberg, A. , Ohm, I.K. & Christensen, H. Cyclosporine A‐ and tacrolimus‐mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab. Dispos. 4, 655–661 (2012).
- Ouwerkerk‐Mahadevan, S. , Snoeys, J. , Peeters, M. , Beumont‐Mauviel, M. & Simion, A. Drug‐drug interactions with the NS3/4A protease inhibitor simeprevir. Clin. Pharmacokinet. 2, 197–208 (2016).
- Lemahieu, W.P.D. et al Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 9, 2236–2243 (2005).
- Wason, S. , DiGiacinto, J.L. & Davis, M.W. Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. Postgrad. Med. 4, 189–196 (2012).
- Christians, U. , Jacobsen, W. , Benet, L.Z. & Lampen, A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 11, 813–851 (2002).
- Hart, A. et al Kidney. Am. J. Transplant. S2, 11–46 (2016).
- Ekberg, H. et al Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 25, 2562–2575 (2007).
- Korn, W.R. , Paziuk, T.M. & Stickle, D.F. Measurement of plasma Apixaban by LC‐MS/MS using the AB Sciex API 3200MD. Clin. Chem. 62, S214 (2016).
- Kenward, M.G. & Roger, J.H. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 3, 983–997 (1997).
- Veeger, N.J.G.M. , Piersma‐Wichers, M. , Tijssen, J.G.P. , Hillege, H.L. & Meer, J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br. J. Haematol. 4, 513–519 (2005).
- Pokorney, S.D. et al Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT‐AF registry. Am. Heart J.. 1, 141–148 (2015).
- Frost, C. et al Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol. 2, 476–487 (2013).
Source: PubMed